close-up-microphone-news-and-events close-up-microphone-news-and-events

Press Releases

MMIT Announces the Winners of the Q4 2022 Patient Access Awards

By Kelly Mullin

Payers and physicians recognize manufacturers across seven therapeutic areas who are dedicated to smoothing patient access

March 30, 2023, Yardley, PA – Managed Markets Insight & Technology (MMIT), the leading provider of market access data, analytics and insights, has announced the winners of its quarterly Patient Access Awards, which honor manufacturers committed to improving patient access to life-saving therapies.

“Bringing innovative drugs to market is just the first step of the equation,” said Diane Watson, CEO of MMIT, a Norstella company. “These companies are recognized not only for their products, but for their dedication to ensuring patient access despite all obstacles.”

The winners—one per therapeutic area—are determined by payer and physician stakeholders, who are surveyed as part of MMIT’s quarterly Oncology Index and Biologics and Injectables Index.

In this research, payer and physician stakeholders assess and rank the performance of manufacturers across a series of factors, including the manufacturer’s overall commitment to a disease, account representative support, patient and family support programs and resources, patient copay assistance, physician education and support, and HUB services.

“Congratulations to each of the winners, all of whom are dedicated making sure that life-saving drugs are available for the patients who need them,” said Watson. “We’re proud of your success and glad to have the opportunity to celebrate your achievements.”

The winners of the Q4 Patient Access Awards are: 

Oncology:

Bristol-Myers Squibb (Liver Cancer)

Bristol-Myers Squibb (Renal Cell Carcinoma) 

Merck & Co. (Colorectal Caner) 

Biologics & Injectables: 

Genentech (Ocular Disease) 

Roche (Hemophilia) 

Takeda (Immunodeficiency) 

Learn more information about the Patient Access Awards.

 

About MMIT

MMIT, a Norstella company, believes that patients who need lifesaving treatments shouldn’t face delays because of the barriers to accessing therapies. As the leading provider of market access data, analytics and insights, our expert teams of pharmacists, clinicians, data specialists and market researchers provide clarity and confidence so that our clients can make better decisions. For more information, visit mmitnetwork.com and follow us on LinkedIn.

0 Comments
Kelly Mullin

Kelly Mullin Digital Marketing Specialist

Related Posts

cms-website
February 23

Panelists: CMS Prior Authorization Rule Should Help, But More Is Needed

READ MORE
blue-cross-blue-shield-image
February 23

Checking on the Blues: Analysts Predict Margin Uptick in ’23 Will Be Short-Lived

READ MORE
techy-illustration
February 23

ONC Head Touts Interoperability Wins, Poses AI Questions

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today